Peptides and TRT: separating bodybuilding lore from evidence

What did @daviddemesquita actually say?

He made a pointed argument that IGF-1 is genuinely risky, not just in a hand-wavy way. His core claim: IGF-1 "does a very poor job at delineating out bad cells from good cells," meaning it can stimulate tumor growth alongside muscle growth. He referenced the Increlex prescribing information, anecdotal deaths among bodybuilders, observations from the late coach John Meadows, and drew a distinction between growth hormone's cancer risk profile and IGF-1's. He stopped short of saying IGF-1 causes cancer outright, but argued it can accelerate existing tumor growth. That's a meaningfully specific claim, and it deserves a careful look rather than a dismissal.

Does the science back this up?

Mostly, yes. The concern here is real and well-documented. IGF-1 signals through the IGF-1 receptor (IGF-1R), which is overexpressed in many solid tumors, including breast, colorectal, and prostate cancers. A 2012 meta-analysis by Rowlands and colleagues in PLOS ONE found elevated serum IGF-1 was associated with increased risk of several cancers. The Increlex (mecasermin) prescribing label does explicitly list neoplasm progression as a safety concern, exactly as the creator described. However, the claim that growth hormone's cancer risk is "almost immeasurable" deserves more nuance. Long-term GH studies, including the SAGhE cohort published in the Journal of Clinical Endocrinology and Metabolism by Carel et al. in 2012, showed a modestly elevated cancer mortality signal in some subgroups, though the absolute risk remained low. So GH is not off the hook either.

What did they get wrong (or right)?

He got the mechanism broadly right. IGF-1 promotes cell proliferation through the PI3K/Akt/mTOR pathway, and that pathway does not meaningfully distinguish between healthy and malignant cells. This is not fringe science. Where the argument gets shakier is in the anecdotal evidence. Citing John Meadows and personal observations of bodybuilders dying from cancer is not evidence. These are individuals who were typically using supraphysiological doses of multiple compounds simultaneously, including anabolic steroids, which carry their own cancer-adjacent risks, particularly for liver and prostate. Attributing those outcomes specifically to IGF-1 is not something the data supports cleanly. The creator is right to flag the risk. But the causal confidence in his framing outruns the evidence when he leans on anecdote over controlled data.

What should you actually know?

IGF-1 is not a banned or underground compound in all contexts. Increlex is FDA-approved for severe primary IGF-1 deficiency in children. The risks flagged on its label are real regulatory concerns, not manufacturer boilerplate. Outside of that narrow approved use, exogenous IGF-1 use in healthy adults sits in a regulatory gray zone and has no established safe dosing protocol for optimization or bodybuilding purposes. The distinction between IGF-1 LR3 and standard IGF-1 that the creator gestures at is real: LR3 is a modified analog with a longer half-life and potentially different receptor binding dynamics, but neither version has robust human safety data in the performance context. Anyone considering peptide therapies that raise IGF-1 indirectly, such as GH secretagogues, should have baseline and follow-up IGF-1 levels monitored by a licensed clinician. This is not optional caution. It is standard practice in responsible prescribing.